Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the group will begin production MAN-19, a clinical grade therapeutic intended to treat complications caused by the coronavirus.
Corin says the Phase 1 clinical trial, which will be conducted with technology partner Mannin Research, is slated to begin patient enrollment in February 2021.
Price: 1.08 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has received a US patent for its Uttrocide-B molecule as a potential liver cancer treatment. Corin says the company now has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology,...
Prev article
